- Main
A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication
- Han, Hesong;
- Gracia, Albert Vallejo;
- Røise, Joachim J;
- Boike, Lydia;
- Leon, Kristoffer;
- Schulze-Gahmen, Ursula;
- Stentzel, Michael R;
- Bajaj, Teena;
- Chen, Dake;
- Li, I-Che;
- He, Maomao;
- Behrouzi, Kamyar;
- Khodabakhshi, Zahra;
- Nomura, Daniel K;
- Mofrad, Mohammad RK;
- Kumar, G Renuka;
- Ott, Melanie;
- Murthy, Niren
- et al.
Published Web Location
https://doi.org/10.1039/d3ra00426kAbstract
Covalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 have great potential as antivirals, but their non-specific reactivity with thiols has limited their development. In this report, we performed an 8000 molecule electrophile screen against PLpro and identified an α-chloro amide fragment, termed compound 1, which inhibited SARS-CoV-2 replication in cells, and also had low non-specific reactivity with thiols. Compound 1 covalently reacts with the active site cysteine of PLpro, and had an IC50 of 18 μM for PLpro inhibition. Compound 1 also had low non-specific reactivity with thiols and reacted with glutathione 1-2 orders of magnitude slower than other commonly used electrophilic warheads. Finally, compound 1 had low toxicity in cells and mice and has a molecular weight of only 247 daltons and consequently has great potential for further optimization. Collectively, these results demonstrate that compound 1 is a promising lead fragment for future PLpro drug discovery campaigns.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-